Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] (the Company) today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) adopted a positive final Opinion on its Paediatric Investigation Plan (PIP) for the development of ATL1102 for Duchenne muscular dystrophy (DMD) following the PDCO meeting on 15 October 2021, with EMA ratification to follow.
”EMA adopted a positive final opinion on its Paediatric Investigation Plan”
The final ratification to follow… ( so it’s a given )
ANP Price at posting:
20.5¢ Sentiment: Buy Disclosure: Held
